Biocon moves up as its arm receives NOC from Health Canada for Yesafili
This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025
Biocon is currently trading at Rs. 352.95, up by 2.40 points or 0.68% from its previous closing of Rs. 350.55 on the BSE.
The scrip opened at Rs. 350.60 and has touched a high and low of Rs. 354.00 and Rs. 350.10 respectively. So far 33497 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 404.60 on 21-Jan-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 356.95 and Rs. 343.15 respectively. The current market cap of the company is Rs. 47241.61 crore.
The promoters holding in the company stood at 54.45%, while public held 45.37% stake in the company.
Biocon’s subsidiary -- Biocon Biologics has received Notice of Compliance (NOC) from Health Canada for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada.
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
